China Resources Boya Bio pharmaceutical Group Co Ltd (300294) — Financial Flexibility Index
China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has a Financial Flexibility Index of 0.14x as of December 2025. Free cash flow of CN¥159.28 Million (operating CF CN¥36.82 Million minus capex CN¥122.46 Million) represents 0% of total liabilities (CN¥1.16 Billion). Also explore net asset momentum of China Resources Boya Bio pharmaceutical to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
China Resources Boya Bio pharmaceutical Group Co Ltd Financial Flexibility Index (2009–2025)
Historical Financial Flexibility Index trend for China Resources Boya Bio pharmaceutical Group Co Ltd across 17 annual periods. Check strategic asset allocation of China Resources Boya Bio pharmaceutical to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for China Resources Boya Bio pharmaceutical Group Co Ltd (2009–2025)
Year-by-year free cash flow to debt coverage for China Resources Boya Bio pharmaceutical Group Co Ltd. For the full company profile including market capitalisation, see market cap of China Resources Boya Bio pharmaceutical .
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.56x | CN¥651.99 Million | CN¥116.69 Million | CN¥1.16 Billion | ▲ +2.7% |
| 2024 | 0.54x | CN¥497.58 Million | CN¥299.78 Million | CN¥913.38 Million | ▼ -62.0% |
| 2023 | 1.44x | CN¥729.22 Million | CN¥641.73 Million | CN¥508.07 Million | ▲ +46.2% |
| 2022 | 0.98x | CN¥734.85 Million | CN¥596.44 Million | CN¥748.35 Million | ▼ -51.3% |
| 2021 | 2.02x | CN¥1.41 Billion | CN¥1.35 Billion | CN¥701.30 Million | ▲ +126.1% |
| 2020 | 0.89x | CN¥861.09 Million | CN¥718.58 Million | CN¥966.08 Million | ▲ +4464.1% |
| 2019 | -0.02x | CN¥-25.90 Million | CN¥-114.51 Million | CN¥1.27 Billion | ▼ -117.9% |
| 2018 | 0.11x | CN¥148.80 Million | CN¥34.90 Million | CN¥1.30 Billion | ▼ -36.7% |
| 2017 | 0.18x | CN¥213.97 Million | CN¥-23.82 Million | CN¥1.19 Billion | ▼ -89.6% |
| 2016 | 1.74x | CN¥498.84 Million | CN¥198.76 Million | CN¥287.30 Million | ▲ +58.7% |
| 2015 | 1.09x | CN¥306.39 Million | CN¥147.02 Million | CN¥280.11 Million | ▼ -39.5% |
| 2014 | 1.81x | CN¥169.78 Million | CN¥121.88 Million | CN¥93.90 Million | ▲ +133.9% |
| 2013 | 0.77x | CN¥122.00 Million | CN¥89.11 Million | CN¥157.85 Million | ▼ -82.9% |
| 2012 | 4.53x | CN¥116.81 Million | CN¥92.36 Million | CN¥25.80 Million | ▲ +210.7% |
| 2011 | 1.46x | CN¥99.79 Million | CN¥81.53 Million | CN¥68.48 Million | ▲ +132.0% |
| 2010 | 0.63x | CN¥61.42 Million | CN¥24.77 Million | CN¥97.79 Million | ▼ -11.1% |
| 2009 | 0.71x | CN¥107.28 Million | CN¥51.88 Million | CN¥151.93 Million | — |